Clinical Trial: Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054034) titled 'Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects' on May 27.

Brief Summary: A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks

Study Start Date: May 11

Study Type: INTERVENTIONAL

Condition: Bronchial Asthma

Intervention: DRUG: MG-ZG122 Humanized Monoclonal Antibody Injection

MG-ZG122 Humanized Monoclonal Antibody Injection

OTHER: Placebo

MG-ZG122 Humanized Monoclonal Antibody Injection Placebo

Recruitment Status: ACTIVE_NOT_RECRUITING...